论文部分内容阅读
目的 观察自由基清除剂依达拉奉(edaravone)对矽肺大鼠造模后肺纤维化的影响,探讨其对矽肺的治疗作用.方法 SPF级Wistar大鼠54只随机等分为9组:对照组,模型组以及依达拉奉干预组,后两组依采样时间分为7、14、21和28 d 4个亚组,每组各6只大鼠.除对照组外,其余各组大鼠采用非暴露法气管内一次性注射二氧化硅(SiO2)悬液(250 mg/kg)复制矽肺动物模型;依达拉奉组自注射SiO2后每天腹腔注射依达拉奉(4 ml/kg),对照组每天用生理盐水腹腔注射(4 ml/kg),连续28 d.采用HE染色技术观察各组大鼠肺组织形态学变化,Western blot检测肺组织中转化生长因子 β(TGF-β)蛋白的表达;试剂盒检测肺组织中羟脯氨酸(HYP)、还原型谷胱甘肽(GSH)和丙二醛(MDA)含量.结果 依达拉奉可改善矽肺大鼠肺间质纤维化程度,提高矽肺大鼠肺组织匀浆GSH活力,降低HYP、TGF-β 和MDA含量.结论 依达拉奉可降低大鼠体内自由基及TGF-β 水平,对矽肺大鼠有较好的治疗作用.“,”Objective To investigate the protective effect of Edaravone on pulmonary fibrosis in rat of penumosilicosis. Methods Rat model of pneumosilicosis was established by daily intratracheal instillation of silica in suspension (250 mg/kg) for consecutive 28 days. Edaravone was intraperitoneally injected on a daily basis at 4 ml/kg. Saline was administrated in control group. Tissues as well as organs were harvested at 7 d, 14 d, 21 d and 28 d. Hematoxylin eosin staining was performed for histological changes of lung tissue. Level of TGF-β was identified by Western blot. Concentration of HYP, GSH and MDA was measured by commercial kits. Results Edaravone significantly ameliorated pulmonary fibrosis when compared with that in penumosilicosis group, improving GSH activity and reducing the levels of HYP, TGF-β and MDA. Conclusions Edaravone exerts therapeutic effect for silicosis by reducing free radical and TGF-β expression.